Pfizer Inc. Market Cap 2010-2024 | PFE

Pfizer Inc. market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer Inc. market cap as of February 24, 2025 is $149.04B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $149.042B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly and Company (LLY) US $828.397B 67.21
Novo Nordisk A/S (NVO) DK $395.262B 26.77
Johnson & Johnson (JNJ) US $390.756B 16.25
AbbVie Inc. (ABBV) US $356.743B 19.97
Roche Holding AG (RHHBY) CH $264.174B 0.00
Merck & Co., Inc. (MRK) US $226.402B 11.72
Novartis AG (NVS) CH $223.511B 14.00
Sanofi (SNY) $138.211B 13.09
Bayer Aktiengesellschaft (BAYRY) DE $22.635B 3.62
Innoviva, Inc. (INVA) US $1.132B 9.42